VCEL Vericel Corporation

15.45
-0.05  -0%
Previous Close 15.5
Open 15.4
Price To Book 7.69
Market Cap 681,915,043
Shares 44,136,896
Volume 258,573
Short Ratio
Av. Daily Volume 479,780
Stock charts supplied by TradingView

NewsSee all news

  1. Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol

    CAMBRIDGE, Mass. and YAVNE, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL) and MediWound Ltd. (NASDAQ:MDWD) today announced initiation of the NexoBrid® expanded access treatment protocol

  2. Vericel to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019

    CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo,

  3. Vericel to Present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019

    CAMBRIDGE, Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, CFO &

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

BLA filing due 2Q 2020.
NexoBrid
Severe burns
Phase 2b topline data released March 2016. Full data released April 2016
ixmyelocel-T
Stem cells - Dilated Cardiomyopathy
FDA Approval announced December 13, 2016 ahead of PDUFA date of January 3 2017.
MACI
Focal chondral cartilage defects in the knee.

Latest News

  1. Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol

    CAMBRIDGE, Mass. and YAVNE, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL) and MediWound Ltd. (NASDAQ:MDWD) today announced initiation of the NexoBrid® expanded access treatment protocol

  2. Vericel to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019

    CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo,

  3. Vericel to Present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019

    CAMBRIDGE, Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, CFO &